GMAB - Genmab AS

Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark.

52W High

$27.62

52W Low

$17.23

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.80

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

14.27

Forward P/E (<15 better)

13.00

EV/EBITDA (<8 favorable)

9.53

EV/Revenue (<3 favorable)

4.31

P/S (TTM) (<3 favorable)

4.65

P/B (<3 favorable)

3.20

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

0.00%

Institutions (25–75% balanced)

10.09%

Shares Outstanding

615,071,000

Float

60,809,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

3,646,881,000

Gross Profit (TTM)

3,447,811,000

EPS (TTM)

1.93

Profit Margin (>10% good)

0.38%

Operating Margin (TTM) (higher better)

0.39%

ROE (TTM) (>15% strong)

0.28%

EPS YoY (Quarterly) (>10% good)

0.73

Revenue YoY (Quarterly) (>8% good)

0.19

Momentum

Bearish momentum

Value

1.6927

1.7377

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025